- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06241846
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a multicenter, open-label, Phase 2 study. The study will enroll subjects with metastatic castration-resistant prostate cancer (mCRPC) previously treated with at least 1 prior line of novel hormone therapy (NHT). NHT includes abiraterone, enzalutamide, apalutamide, darotamide, or rezvilutamide. Subjects must have received no more than 2 prior lines of taxane-containing regimen.
This study consists of two parts. Part 1 will preliminarily assess the efficacy and tolerability of YL201 at 2.0, 2.4, or 2.8 mg/kg with approximately 40 subjects. Part 2 will further assess the efficacy and safety of YL201 at the recommended expansion dose (RED) obtained from Part 1 with up to 60 subjects.
YL201 will be administered intravenously (IV) on Day 1 of each 3-week cycle until criteria of treatment discontinuation are met. Subjects will undergo regular testing for signs of disease progression (PD) using computed tomography (CT) scan, magnetic resonance imaging (MRI), bone scan, and prostate-specific antigen (PSA) blood test. Routine examinations and blood tests will be performed and evaluated by the study physician.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sasha Stann
- Phone Number: 06172408494
- Email: sasha@medilinkthera.com
Study Contact Backup
- Name: Steve Chin, Ph.D.
- Phone Number: 06178719455
- Email: info@medilinkthera.com
Study Locations
-
-
-
Shanghai, China
- Recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Site Coordinator
-
-
Anhui
-
Hefei, Anhui, China
- Not yet recruiting
- Anhui Provincial Hospital
-
Contact:
- Site Coordinator
-
-
Beijing
-
Peking, Beijing, China
- Not yet recruiting
- Peking University First Hospital
-
Contact:
- Site Coordinator
-
Peking, Beijing, China
- Not yet recruiting
- Peking University Third Hospital
-
Contact:
- Site Coordinator
-
-
Changsha
-
Hunan, Changsha, China
- Not yet recruiting
- Hunan Cancer Hospital
-
Contact:
- Site Coordinator
-
-
Chongqing
-
Chongqing, Chongqing, China
- Not yet recruiting
- Chongqing University Cancer Hospital
-
Contact:
- Site Coordinator
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Not yet recruiting
- Nanjing Drum Tower Hospital
-
Contact:
- Site Coordinator
-
Nantong, Jiangsu, China
- Not yet recruiting
- Nantong Tumor Hospital
-
Contact:
- Site Coordinator
-
-
Tianjin
-
Tianjin, Tianjin, China
- Not yet recruiting
- The Second Hospital Of Tianjin Medical University
-
Contact:
- Site Coordinator
-
-
Zhejiang
-
Ningbo, Zhejiang, China
- Recruiting
- Ningbo Yinzhou No.2 Hospital
-
Contact:
- Site Coordinator
-
Wenzhou, Zhejiang, China
- Not yet recruiting
- The First Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Site Coordinator
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who understand relevant information of the study prior to initiation of the study and voluntarily sign and date on the ICF.
- Age ≥ 18 years.
- Patients who are histologically or cytologically confirmed prostate cancer.
- Patients with metastatic lesions confirmed by CT, MRI, or bone scan imaging within 28 days prior to the first dose.
- Patients with archived or fresh tumor tissue samples. Patients who cannot provide tumor samples or cannot provide sufficient samples may be enrolled in this study after considering specific circumstances and discussions with the Sponsor.
- Eastern cooperative oncology group performance status (ECOG PS) score of 0 or 1.
- The function of organs and bone marrow meets the requirements within 7 days prior to the first dose.
- Patients must agree to adopt highly effective contraceptive measures from screening, throughout the study period, and within at least 6 months after the last dose of the investigational drug.
- Expected survival ≥ 6 months.
- Be capable of and willing to comply with the visits and procedures stipulated in the study protocol.
Exclusion Criteria:
- Previously treated with drugs targeting B7H3.
- Currently participating in another clinical study, unless it is an observational (non-interventional) clinical study, or the patient is at the follow-up period of an interventional study.
- Previously treated with topoisomerase I inhibitors or ADC therapy composed of topoisomerase I inhibitors.
- The washout period of the previous anti-tumor therapy is considered insufficient.
- Patients received major surgery.
- Prior treatment with allogeneic bone marrow transplantation or solid organ transplantation.
- Prior treatment with glucocorticoids for more than 28 consecutive days within 28 days prior to the first dose of the investigational drug.
- Patients received any live vaccine within 4 weeks prior to the first dose of the investigational drug, or plan to receive live vaccine during the study period.
- Have pathological long bone fracture, or the risk of pathological long bone fracture.
- Have meningeal metastasis or cancerous meningitis.
- Have uncontrolled bladder outlet obstruction or urinary incontinence.
- Have brain metastasis or spinal cord compression.
- Patients with uncontrolled or clinically significant cardiovascular diseases.
- Clinically significant complicated pulmonary disorders.
- Diagnosed with Gilbert's syndrome.
- Accompanying uncontrolled effusion in the third space requiring repeated drainage.
- Medical history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose, or active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal diseases that may cause hemorrhage or perforation in the opinion of the investigator.
- Active serious infection (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] ≥ 3) within 4 weeks prior to the first dose.
- Known human immunodeficiency virus (HIV) infection.
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Diagnosed with the other malignancies that may change the expected survival or affect the response evaluation.
- Unresolved toxicity of previous anti-tumor therapy.
- History of severe hypersensitivity to inactive ingredients in the drug substance and drug product or other monoclonal antibodies.
- Have any diseases, medical conditions, organ system dysfunction, or social conditions that may interfere with the subject ability to sign the ICF, adversely affect the subject ability to cooperate and participate in the study, or affect the interpretation of study results, including but not limited to mental illness or substance/alcohol abuse, in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1
Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
|
Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
|
Experimental: Part2
Patients will be treated with YL201 intravenous (IV) infusion at recommended dose of YL201 for the pivotal clinical study once every 3 weeks (Q3W) as a cycle.
|
Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) by RECIST1.1 and PCWG3 criteria per investigators' review
Time Frame: Approximately within 36 months
|
defined as percentage of participants with confirmed best overall response of confirmed complete response (CR) or partial response (PR) to treatment
|
Approximately within 36 months
|
Radiographic progression free survival (rPFS), and rPFS rate at 3/6 months by RECIST1.1 and PCWG3 criteria per investigators' review
Time Frame: Approximately within 36 months
|
defined as the time from the date of first administration to first documented progressive disease (PD) per RECIST1.1 and PCWG3 or death from any cause, whichever occurs first.
|
Approximately within 36 months
|
Recommended dose of YL201 for the pivotal clinical trial.
Time Frame: Approximately within 36 months
|
Approximately within 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
disease control Rate (DCR) by RECIST1.1 and PCWG3 criteria per investigators' review
Time Frame: Approximately within 36 months
|
Disease control rate
|
Approximately within 36 months
|
To evaluate DoR by RECIST1.1 and PCWG3 criteria per investigators' review of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
Duration of rasponse
|
Approximately within 36 months
|
To evaluate TTR of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
Time to Objective response
|
Approximately within 36 months
|
To evaluate DpR of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
deepness of response
|
Approximately within 36 months
|
To evaluate TTPR of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
time to PSA response
|
Approximately within 36 months
|
To evaluate PDoR of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
PSA duration of response
|
Approximately within 36 months
|
To evaluate PDpR of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
PSA deepness of response
|
Approximately within 36 months
|
To evaluate TTPP of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
time to PSA progression
|
Approximately within 36 months
|
To evaluate TFST of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
time to first subsequent therapy
|
Approximately within 36 months
|
To evaluate rPFS of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
Radiographic Progression Free Survival
|
Approximately within 36 months
|
To evaluate OS of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
overall survival
|
Approximately within 36 months
|
To evaluate time to first symptomatic skeletal event of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
assessed by investigator according to RECIST v1.1 and PCWG3 criteria
|
Approximately within 36 months
|
To evaluate the AUC of YL201
Time Frame: Approximately within 36 months
|
the area under curve: AUC is the total amount of YL201 in bloodstream after drug administration
|
Approximately within 36 months
|
To evaluate the Cmax of YL201
Time Frame: Approximately within 36 months
|
Maximum concentration: The highest measured concentration of YL201 in the bloodstream.
|
Approximately within 36 months
|
To evaluate the Ctrough of YL201
Time Frame: Approximately within 36 months
|
trough concentration
|
Approximately within 36 months
|
To evaluate the CL of YL201
Time Frame: Approximately within 36 months
|
Clearance: defined as the amount of drug removed from the bloodstream by the body per unit of time
|
Approximately within 36 months
|
To evaluate the Vd of YL201
Time Frame: Approximately within 36 months
|
volume of distribution
|
Approximately within 36 months
|
To evaluate the T1/2 of YL201
Time Frame: Approximately within 36 months
|
Terminal half-life: defined as the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%
|
Approximately within 36 months
|
To evaluate the immunogenicity of YL201
Time Frame: Approximately within 36 months
|
Approximately within 36 months
|
|
To evaluate PSA50 response rate and PSA50 response rate at 12 weeks of YL201 in the treatment of mCRPC
Time Frame: Approximately within 36 months
|
PSA50 response is defined as a ≥ 50% decline in PSA from baseline with PSA confirmation ≥ 3 weeks after the first documented reduction in PSA of ≥ 50%.
|
Approximately within 36 months
|
Expression of B7H3 in tumor tissue at baseline and the relationship with the efficacy of YL201.
Time Frame: Approximately within 36 months
|
Approximately within 36 months
|
|
Number of participants with AEs, SAEs, and SAEs leading to study treatment interruption or discontinuation.
Time Frame: Approximately within 36 months
|
adverse event, serious adverse event
|
Approximately within 36 months
|
To evaluate the E-R relationship of YL201
Time Frame: Approximately within 36 months
|
exposure-response
|
Approximately within 36 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YL201-CN-201-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
BayerCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)United States
-
BayerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.CompletedMetastatic Castration-resistant Prostate Cancer (mCRPC)China
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.CompletedProstate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)United States
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingMetastatic Castration-Resistant Prostate Cancer (mCRPC)Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
-
Constellation PharmaceuticalsActive, not recruitingMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
Avionco LLCCompletedMetastatic Castration-Resistant Prostate Cancer (mCRPC)Russian Federation
-
UNC Lineberger Comprehensive Cancer CenterWithdrawnMetastatic Castration Resistant Prostate Cancer (mCRPC)United States
-
PfizerCompletedMetastatic Castration Resistant Prostate Cancer (mCRPC) | Metastatic Castration Sensitive Prostate Cancer (mCSPC)Finland
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
Clinical Trials on YL201 for Injection
-
MediLink Therapeutics (Suzhou) Co., Ltd.Recruiting
-
MediLink Therapeutics (Suzhou) Co., Ltd.Recruiting
-
Bio-Thera SolutionsNot yet recruiting
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, United States, Taiwan, Turkey, Georgia
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
Aro BiotherapeuticsRecruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting